BURTON UPON TRENT, England–(BUSINESS WIRE)–Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global
pharmaceutical and services company, has appointed James (‘Jim’) Meyer
as General Manager, Commercial Medicines, US, with immediate effect.
Jim Meyer is an accomplished and seasoned executive with nearly 40 years
of experience in the pharmaceutical industry, of which included five
years at Teva Pharmaceuticals where he led the Oncology New Products
Division in the US. As the Oncology Lead, he was responsible for the
commercial development and launch of multiple oncology products.
Additionally, he played a key role in the development of commercial
strategy and business development for the US oncology business unit.
Prior to Teva, Jim spent over 27 years at Wyeth (now Pfizer) in a
variety of commercial roles across multiple therapeutic areas, including
oncology.
Jim will be responsible for delivering on the Group’s strategy in
Commercial Medicines in the US. Specifically, he has been appointed to
build out Clinigen’s commercial infrastructure in the US and to
capitalise on other opportunities across the business. This follows on
from the acquisition of Proleukin® in April 2019 which
created an ideal platform to expand the Group’s existing footprint in
the higher value US market where it currently owns the US rights to
Foscavir®, Ethyol® and Totect®, all of
which are distributed by third parties. Jim’s appointment demonstrates
the Group’s intent to build upon this opportunity.
Benjamin Miny, Senior Vice President of Commercial Medicines,
Clinigen Group, said:
“Jim brings in depth experience and a deep understanding of US-based
oncology sales and marketing. With this background, he is particularly
suited to building and leading the US commercial infrastructure Clinigen
needs to support its ambitions in this market, especially following the
acquisition of Proleukin. On behalf of the team, I welcome Jim to
Clinigen and look forward to working with him.”
Jim Meyer, General Manager of Commercial Medicines, US, Clinigen
Group, said:
“Joining Clinigen at this important time in its development is a real
opportunity, and I look forward to helping with the expansion of
Clinigen’s Commercial Medicines business in the US. The acquisition of
Proleukin’s US rights gives a great platform for the Company to grow
from in North America. I believe my experience from Teva and Wyeth will
help propel Clinigen forward in this market.”
-Ends-
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services
company with a unique combination of businesses focused on providing
ethical access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time through three areas of
global medicine supply; clinical trial, unlicensed and licensed
medicines. The Group has sites in North America, Europe, Africa and Asia
Pacific. In October 2018, the Group acquired CSM, a specialist provider
of packaging, labelling, warehousing and distribution services, with
sites in the US and Europe, and iQone, a specialist pharmaceutical
company in Switzerland.
For more information, please visit www.clinigengroup.com
Contacts
Clinigen Group plc
Benjamin Miny, Senior Vice President of
Commercial Medicines
Matt Parrish, Head of Investor Relations
Tel:
+44 (0) 1283 495010
Instinctif Partners
Melanie Toyne-Sewell / Alex Shaw /
Deborah Bell
Tel: +44 (0) 20 7457 2020
Email: clinigen@instinctif.com